LUND, SWEDEN -- 05/15/08 --
Lund, Sweden - 15 May 2008 - Active Biotech
(OMX Nordic: ACTI)
management is scheduled to present at the Rodman & Renshaw Annual
Global Healthcare Conference next week at 10:00 AM CEST on Tuesday,
20 May at Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco. During
the presentation, an update will be provided on the Active Biotech
development program.
The company has five projects in clinical development for the
treatment of serious autoimmune/inflammatory diseases and cancer.
Laquinimod - a novel oral treatment of multiple sclerosis - is
developed through a cooperation with Teva Pharmaceutical Industries
Ltd and is currently in Phase III global clinical trials in US,
Europe and Israel with approximately 2 200 patients. ANYARA - a novel
cancer targeted therapy - is in Phase III trials with 500 advanced
renal cell cancer patients. Further key projects in clinical
development comprise three orally administered compounds; TASQ for
prostate cancer in Phase II, 57-57 for Systemic Lupus Erythematosus
(SLE) in Phase Ib and RhuDex® (licensed to MediGene AG) for
Rheumatoid Arthritis (RA) in Phase IIa.
The Active Biotech audio and slide presentation will be web cast live
on 20 May, at
10:00 AM CEST. A replay will be available approximately two hours
following the presentation and archived on the company's web site.
To access the live and replay presentations, visit the Active Biotech
web site - www.activebiotech.com.
The complete Conference Schedule can be accessed at:
www.rodmanandrenshaw.com/eu08conference
Active Biotech AB is a biotechnology company focusing on research and
development of pharmaceuticals. Active Biotech has a strong R&D
portfolio with pipeline products focused on autoimmune/inflammatory
diseases and cancer. Most advanced projects are laquinimod, an orally
administered small molecule with unique immunomodulatory properties
for the treatment of multiple sclerosis, as well as ANYARA for use in
cancer targeted therapy, the primary indication being renal cancer.
Further key projects in clinical development comprise the three
orally administered compounds TASQ for prostate cancer, 57-57 for SLE
and RhuDex® for RA.
Contacts:
Active Biotech AB
Cecilia Hofvander
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Direct: +46 (0)46 19 11 22
Fax: +46 (0)46-19 20 50
www.activebiotech.com
Copyright © Hugin AS 2008. All rights reserved.
